Roivant Sciences (ROIV) Reiterated at Overweight by Cantor Fitzgerald: 'Thesis Unchanged'

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Roivant Sciences (NASDAQ: ROIV).

The analyst commented, "We are updating our model for revenue, near-term milestones and license revenues (e.g., with Genevant) and operating expense estimates following FY1Q earnings. Our ROIV OW thesis is unchanged."

For an analyst ratings summary and ratings history on Roivant Sciences click here. For more ratings news on Roivant Sciences click here.

Shares of Roivant Sciences closed at $36.36 yesterday.

You May Also Be Interested In

• Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
• Scotiabank Starts SoFi Technologies (SOFI) at Sector Outperform
• Increasing unusual put volume: A ARRY DBX JXN BAM FIGR XRX ALT STNE FAST CG PAGP